MONICA ARNEDOS

Institut Bergonié

France

Research Interests

Explore related searches

Professors in France Professors in Cancer Biology Cancer Biology professors in France

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (12)

Year:

2025

Year:

2024

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Collaborators (6)

Ivan Bieche

Université Paris Cité

FRANCE

View details

Valerio Iebba

Assistant Professor

University of Trieste

ITALY

View details

Marta Santisteban

Clinica Universidad de Navarra

SPAIN

View details

Jeremy Braybrooke

Honorary Associate Professor

University of Bristol

UNITED KINGDOM

View details

Peter Lucas

Professor and Vice Chair

University of Pittsburgh School of Medicine

UNITED STATES

View details

Anne Patsouris

Institut de Cancérologie de l'Ouest

FRANCE

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

MONICA ARNEDOS

Research Interests

Explore related searches

Contact this professor

Articles (12)

Real-world treatment patterns and effectiveness after disease progression on CDK4/6 inhibitors for HR-positive/HER2-negative metastatic breast cancer in the ESME-MBC cohort

Elacestrant in ESR1-mutant, endocrine-responsive metastatic breast cancer: should health authorities consider post hoc data to inform priority access?

Genomics to select treatment for patients with metastatic breast cancer.

An immunological signature to predict outcome in patients with triple-negative breast cancer with residual disease after neoadjuvant chemotherapy.

Natural History and Characteristics of ERBB2-mutated Hormone Receptor-positive Metastatic Breast Cancer: A Multi-institutional Retrospective Case-control Study from AACR Project GENIE.

Adjuvant Olaparib for Patients with <i>BRCA1</i>- or <i>BRCA2</i>-Mutated Breast Cancer.

Rucaparib in patients presenting a metastatic breast cancer with homologous recombination deficiency, without germline BRCA1/2 mutation.

A phase II randomised study of preoperative trastuzumab alone or combined with everolimus in patients with early HER2-positive breast cancer and predictive biomarkers (RADHER trial).

Optimizing the Management of Cancer Patients Treated With Systemic Therapies During the COVID-19 Pandemic: The New Role of PCR and CT Scan.

QualFatigue study: which factors influence the use of specific interventions for breast cancer survivors with fatigue? A cross-sectional exploratory study.

Durvalumab compared to maintenance chemotherapy in metastatic breast cancer: the randomized phase II SAFIR02-BREAST IMMUNO trial.

Ketogenic diet and ketone bodies enhance the anticancer effects of PD-1 blockade.

Collaborators (6)

Ivan Bieche

Valerio Iebba

Marta Santisteban

Jeremy Braybrooke

Peter Lucas

Anne Patsouris

Make your next move.